Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bogaerts

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Cancer Treatment Reviews|December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug developmentR Stahel, J Bogaerts, F Ciardiello, et al.
The Journal of Infectious Diseases|August 9, 2001
Local production of anti-vibrio cholerae mucosal antibody in reproductive tract tissues after choleraE T Ryan, E A Bridges, T I Crean, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2008
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)E A Eisenhauer, P Therasse, J Bogaerts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trialG Viale, L Slaets, J Bogaerts, et al.
Breast Cancer Research and Treatment|September 21, 2017
Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trialG Viale, F A de Snoo, L Slaets, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2018
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approachR Galot, C Le Tourneau, J Guigay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2014
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trialH Bonnefoi, S Litière, M Piccart, et al.
Journal of the National Cancer Institute|January 30, 2009
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapyJ L Lefebvre, F Rolland, M Tesselaar, et al.
ESMO Open|April 22, 2021
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoringB Gyawali, E G E de Vries, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Cancer Treatment Reviews|December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug developmentR Stahel, J Bogaerts, F Ciardiello, et al.
The Journal of Infectious Diseases|August 9, 2001
Local production of anti-vibrio cholerae mucosal antibody in reproductive tract tissues after choleraE T Ryan, E A Bridges, T I Crean, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2008
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)E A Eisenhauer, P Therasse, J Bogaerts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trialG Viale, L Slaets, J Bogaerts, et al.
Breast Cancer Research and Treatment|September 21, 2017
Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trialG Viale, F A de Snoo, L Slaets, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2018
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approachR Galot, C Le Tourneau, J Guigay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2014
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trialH Bonnefoi, S Litière, M Piccart, et al.
Journal of the National Cancer Institute|January 30, 2009
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapyJ L Lefebvre, F Rolland, M Tesselaar, et al.
ESMO Open|April 22, 2021
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoringB Gyawali, E G E de Vries, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Pageof 13